The balance sheet reflects severe distress, evidenced by a current ratio of 0.09 and a shift into negative equity of $11.0K as of 2023Q3.
| Total Current Assets | 1.13K | 9.11M | 6.56M | 1.13M | 1.21M | 797.2K |
| Cash & Short-Term Investments | 733 | 7.44M | 6.14M | 762.8K | 15.96K | 431.9K |
| Cash Only | 733 | 7.44M | 6.14M | 762.8K | 15.96K | 431.9K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 362.76K | 137.35K | 41.75K | 60.9K | 39.55K |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | -39.55K |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 71 | 47.19K | 35.96K | 0 | 917.12K | 0 |
| Total Non-Current Assets | 5 | 8.46M | 756.1K | 5.49K | 257.73M | 255.25M |
| Property, Plant & Equipment | 5 | 6.06K | 11.1K | 5.49K | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 45.18M | 8.45M | 745K | 0 | 257.73M | 255M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 248.65K |
| Total Assets | 1.13K | 17.57M | 7.32M | 1.13M | 258.93M | 326.55M |
| Asset Turnover | 0.00x | - | - | - | - | - |
| Asset Growth % | -382.11% | 140.11% | 546.23% | -99.56% | -20.71% | - |
| Total Current Liabilities | 12.1K | 623.19K | 594.37K | 12.1M | 14.27M | 142.67K |
| Accounts Payable | 562 | 229.51K | 261.94K | 562.35K | 1.63M | 36.89K |
| Days Payables Outstanding | - | - | 22.4K | 855.24K | - | - |
| Short-Term Debt | 10.45K | 0 | 0 | 10.45M | 685K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 969 | 309K | 281.95K | 968.51K | 11.8M | 10.91K |
| Current Ratio | 0.09x | 14.62x | 11.04x | 0.09x | 0.08x | 5.59x |
| Quick Ratio | 0.09x | 14.62x | 11.04x | 0.09x | 0.08x | 5.86x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 16.24M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 16.24M |
| Total Liabilities | 12.1K | 623.19K | 594.37K | 12.1M | 14.27M | 16.38M |
| Total Debt | 10.45K | 0 | 0 | 10.45M | 685K | 0 |
| Net Debt | 9.71K | -7.44M | -6.14M | 9.69M | 669.04K | -431.9K |
| Debt / Equity | -0.95x | - | - | - | 0.00x | - |
| Debt / EBITDA | -0.01x | - | - | - | 0.06x | - |
| Net Debt / EBITDA | -0.01x | - | - | - | 0.06x | -0.22x |
| Interest Coverage | -58.97x | -727.46x | 110.15x | -965.34x | - | - |
| Total Equity | -10.97K | 16.94M | 6.72M | -10.97M | 244.66M | 301.6M |
| Equity Growth % | -400.21% | 152.07% | 161.26% | -104.48% | -18.88% | - |
| Book Value per Share | -0.00 | - | 11.83 | -1.68 | 7.49 | 9.23 |
| Total Shareholders' Equity | -10.97K | 16.94M | 6.72M | -10.97M | 244.66M | 236.65M |
| Common Stock | 46.13K | 78.75M | 61.75M | 46.13M | 258.55M | 255M |
| Retained Earnings | -57.46K | -63.38M | -56.45M | -57.46M | -13.9M | -18.36M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 361 | 396.18K | 351.2K | 361.06K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding exhaustion
As reported in financial statements, PBM's total assets plummeted from over $250M in 2022Q3 to just $1.1K by 2023Q3, reflecting a severe contraction in the company's resource base that underscores the precarious nature of its current clinical-stage development trajectory and long-term viability.
The dramatic decline in asset value suggests that the company has undergone significant restructuring or asset impairment, leaving it with a negligible balance sheet. This trajectory indicates that the firm is operating with minimal financial cushion, making it highly susceptible to any operational delays or unforeseen clinical trial costs.
Based on recent SEC filings, the company's current ratio has deteriorated to a precarious 0.09 as of 2023Q3, indicating that current liabilities vastly outweigh available liquid assets and leaving the firm with virtually no buffer to manage its ongoing clinical trial burn rate.
The inability to cover short-term obligations suggests that the company is entirely dependent on external financing or milestone-based capital injections to remain a going concern. Investors should monitor the cash runway closely, as the current liquidity profile provides almost no margin for error in executing the Phase IIb trial.
According to historical balance sheet data, PBM's debt levels reached $10.4K in 2023Q3, a figure that, while small in absolute terms, represents a significant burden for a pre-revenue entity with negative equity of $11.0K, signaling a reliance on debt to fund basic operational survival.
The presence of debt on a balance sheet devoid of revenue suggests that the company is utilizing high-cost or dilutive financing to bridge its funding gaps. This leverage, however minor, complicates the capital structure and may limit the firm's flexibility in negotiating future equity-based funding rounds.
As indicated by the reported figures, the company's equity position has shifted into a negative $11.0K balance as of 2023Q3, a trend that highlights the cumulative impact of persistent net losses and the erosion of shareholder value since the company's public listing.
Negative equity is a strong indicator of financial distress, suggesting that the company's liabilities have effectively consumed its entire capital base. This situation warrants further investigation into the company's ability to attract new capital without further diluting existing shareholders to an extreme degree.
Quick answers to the most common questions about buying PBM stock.
As of 2025, Psyence Biomedical Ltd. (PBM) had total assets of $17.6M including $9.1M in current assets.
Psyence Biomedical Ltd. (PBM) carries total debt of $0.0M, offset by $7.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Psyence Biomedical Ltd. (PBM) has total shareholders' equity (book value) of $16.9M. Book value represents the net worth of the company belonging to common stock holders.
Psyence Biomedical Ltd. (PBM) reported a current ratio of 14.62x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.